A Review Article on Safety and Efficacy of Newer Oral Anticoagulants in the Treatment of Cerebral Venous Sinus Thrombosis

Alwy Joseph,M V Prathvi,Roshiny Thankam James
DOI: https://doi.org/10.52403/ijrr.20230765
2023-07-19
International Journal of Research and Review
Abstract:CVST (Cerebral Venous Sinus thrombosis) is an uncommon and complex illness with gender-specific origins and a wide range of clinical manifestations. It is also a rare kind of stroke that can be lethal if misdiagnosed or treated late. The reasons for this vary across industrialized and developing countries. It is distinguished by a clinical spectrum that is very varied, difficult diagnosis, various etiologies, and a prognosis that necessitates exceptional medical skills and a high suspicious score. When compared to vitamin K antagonists, NOACs had a roughly 50% decreased incidence of intracerebral hemorrhage. Direct oral anticoagulants have been the first-line medications used to treat this illness, but in this expanding world, newer oral anticoagulants such as Apixaban, Dabigatran, Rivaroxaban, and Edoxaban are being employed. Keywords: Cerebral venous Sinus Thrombosis, Newer oral anticoagulants, Factor X A, Apixaban, Dabigatran, Rivaroxaban, Edoxaban
What problem does this paper attempt to address?